The trading price of Nektar Therapeutics (NASDAQ:NKTR) closed lower on Monday, April 01, closing at $0.90, -3.22% lower than its previous close.
In examining the 52-week price action we see that the stock hit a 52-week high of $1.12 and a 52-week low of $0.41. Over the past month, the stock has gained 27.34% in value.
Nektar Therapeutics, whose market valuation is $166.01 million at the time of this writing, is expected to release its quarterly earnings report May 07, 2024 – May 13, 2024. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by -$0.19 per share this quarter, however they have predicted annual earnings per share of -$0.88 for 2024 and -$0.71 for 2025. It means analysts are expecting annual earnings per share growth of 39.30% this year and 19.30% next year.
Analysts have forecast the company to bring in revenue of $15.34 million for the current quarter, with the likely lows of $5.4 million and highs of $20.62 million. From the analysts’ viewpoint, the consensus estimate for the company’s annual revenue in 2024 is $67.51 million. The company’s revenue is forecast to drop by -25.10% over what it did in 2024.
A company’s earnings reviews provide a brief indication of a stock’s direction in the short term, where in the case of Nektar Therapeutics No upward and no downward comments were posted in the last 7 days. On the technical side, indicators suggest NKTR has a 100% Buy on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 100% Buy, while an average of long term indicators suggests that the stock is currently 100% Buy.
A quick review shows that NKTR’s price is currently 2.35% off the SMA20 and 23.73% off the SMA50. The RSI metric on the 14-day chart is currently showing 58.36, and weekly volatility stands at 6.69%. When measured over the past 30 days, the indicator reaches 8.64%. Nektar Therapeutics (NASDAQ:NKTR)’s beta value is currently sitting at 0.91, while the Average True Range indicator is currently displaying 0.07.
To see how Nektar Therapeutics stock has been performing in comparison to its peers in the industry, here are the numbers: NKTR stock’s performance was -3.22% in the latest trading, and 24.50% in the past year.
An evaluation of the daily trading volume of Nektar Therapeutics (NASDAQ:NKTR) indicates that the 3-month average is 1.61 million. However, this figure has increased over the past 10 days to an average of 1.03 million.
Currently, records show that 191.38 million of the company’s shares remain outstanding. The insiders hold 2.98% of outstanding shares, whereas institutions hold 65.06%. The stats also highlight that short interest as of Mar 15, 2024, stood at 2.51 million shares, resulting in a short ratio of 0.93 at that time. From this, we can conclude that short interest is 1.37% of the company’s total outstanding shares. It is noteworthy that short shares in March were up slightly from the previous month’s figure, which was 2.45 million. However, since the stock’s price has seen 60.02% year-to-date, investors’ interest is likely to be reignited due to its potential to move even higher.
